News
The FDA says shortages of GLP-1s are over, but many patients are still getting what are essentially copied medications.
Novo Nordisk faces a critical phase with its obesity drug Wegovy as it confronts competition from Eli Lilly and potential job ...
It’s the most high-profile example yet of a controversial industry practice called preferred pharmacy networks, or PPNs ...
Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...
Weight loss medications like Wegovy can be life-changing for people living with obesity or excess weight with related health ...
20hOpinion
The market is driving prices on GLP-1 drugs down, and an added benefit is lower spending on food.
The maker of Ozempic and Wegovy obesity drugs said some of the prices could come down, as President Trump called for drugmakers to immediately lower their prices for Medicaid. This comes as Novo ...
Indian pharmaceutical companies are preparing to launch generic versions of Novo Nordisk's weight-loss drug, semaglutide, potentially reducing its price by up to 80%.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback